Table 2.
Demographic, clinical and biological characteristics of patients with and without coronavirus disease 2019 at admission included in cohort B, according to prehospitalization antiplatelet agent treatment.
| No prehospitalization APAs (n = 2251) | Prehospitalization APAs (n = 627) | P | |
|---|---|---|---|
| Male sex | 1252 (55.6) | 414 (66.0) | < 0.001 |
| Age (years) | 64.12 ± 17.29 | 75.65 ± 11.99 | < 0.001 |
| BMI (kg/m2) | 28.00 ± 6.12 | 27.23 ± 5.67 | 0.008 |
| Platelet count (g/L) | 221.31 ± 100.10 | 217.35 ± 96.00 | 0.38 |
| Co-morbidities | |||
| Hypertension | 973 (43.5) | 480 (76.9) | < 0.001 |
| Hyperlipidaemia | 445 (19.9) | 355 (56.9) | < 0.001 |
| Diabetes | 410 (18.3) | 267 (42.9) | < 0.001 |
| Coronary artery disease or MI | 293 (13.0) | 334 (53.3) | < 0.001 |
| Stroke | 130 (5.9) | 123 (9.8) | < 0.001 |
| Asthma | 167 (7.4) | 22 (3.5) | < 0.001 |
| COPD | 98 (4.4) | 66 (10.5) | < 0.001 |
| Chronic kidney disease | 249 (11.2) | 156 (25.3) | < 0.001 |
| Active or history of malignancy | 290 (12.9) | 125 (19.9) | < 0.001 |
| History of VTEa | 164 (7.3) | 48 (7.7) | 0.82 |
| Clinical outcomes | |||
| Median length of hospitalization (days) | 8.65 ± 5.61 | 9.58 ± 6.31 | 0.005 |
| Mechanical ventilation | 293 (13.0) | 77 (12.3) | 0.68 |
| In-hospital mortality | 230 (10.2) | 132 (21.1) | < 0.001 |
Data are expressed as number (%) or mean ± standard deviation. APAs: antiplatelet agents; BMI: body mass index; COPD: chronic obstructive pulmonary disease; MI: myocardial infarction; VTE: venous thrombosis event.
a
VTE was defined as deep venous thrombosis and/or pulmonary embolism during hospitalization.